QRFT0.430%
as of Jul 8
AMGN
GrowthAMGEN INC
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Close · 3M
-3.40%
Held by 2 AI ETFs
PQUS0.220%
as of Jul 21
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals5
Win rate100% (5/5)
Avg buy return+6.09%
QRFT · Weight increase · 2d
AMGN, currently priced at $347.01, sits at 89% of its 52-week high, experiencing a +5.3% return over the past 30 days after a -5.2% dip in the preceding 90 days. This recent positive momentum, combined with its position near the top of its annual range, likely influenced Qraft AI's decision within QRFT. The AI, blending traditional factors like momentum and value with proprietary alternative-data overlays for its diversified large-cap core portfolio, increased AMGN's weight consecutively from 0.3900% to 0.4100% between June 18 and June 23. This move suggests the system found sufficient favorable signals in AMGN's 9.07% revenue growth and 89.41% return on equity to adjust its allocation, despite the stock's 24.01 PER and 20.36 PBR, and its current price level.
weight 0.390% → 0.410% (+0.020 pp)·stock up 2.8% in the 30 days before
Jun 23·entry $347.01·now $364.17Drifting
+4.95%
since Jun 23
QRFT · Weight increase · 3d
weight 0.370% → 0.410% (+0.040 pp)·stock up 5.6% in the 30 days before
Jun 5·entry $349.58·now $364.17Drifting
+4.17%
since Jun 5
QRFT · Weight increase · 2d
weight 0.370% → 0.400% (+0.030 pp)·stock up 4.9% in the 30 days before
Jun 4·entry $345.60·now $364.17Drifting
+5.37%
since Jun 4
QRFT · Weight decrease · 2d
The AI ETF likely reduced AMGN's weight due to its premium valuation, reflected in its high PBR, suggesting the model perceives the stock as overvalued relative to its growth prospects or an increase in sector-specific risks. For a retail investor, this signals a need to critically evaluate if AMGN's current market price is justified by its future growth trajectory and competitive landscape, rather than being swayed by strong historical ROE alone.
weight 0.420% → 0.380% (-0.040 pp)·stock down 6.9% in the 30 days before
May 4·entry $323.85·now $364.17
+12.45%
since May 4
QRFT · Weight decrease · 2d
The AI likely reduced AMGN's weight due to its exceptionally high PBR of 20.36, indicating potential overvaluation despite strong revenue growth and ROE. This suggests the algorithm prioritizes valuation and risk management, possibly anticipating limited future upside or a market correction. Retail investors should consequently scrutinize high valuation ratios alongside strong fundamentals, as even profitable companies can be deemed overvalued by sophisticated models.
weight 0.430% → 0.410% (-0.020 pp)·stock down 3.7% in the 30 days before
Apr 27·entry $340.18·now $364.17
+7.05%
since Apr 27
PQUS · Weight decrease · 2d
AMGEN’s 89.41% Return on Equity and 9.07% Revenue Growth initially aligned with Pictet Asset Management's AI ranking system for US large-cap companies within PQUS. However, the stock’s valuation, evidenced by a Price-to-Earnings ratio of 25.16 and Price-to-Book ratio of 20.36, provided a counterpoint to its operational strength. The fund initiated a consecutive weight decrease on July 16 and 17, 2026, reducing AMGEN's allocation from 0.27% to 0.21%. This adjustment, reflecting the AI's rebalancing logic and measured turnover, coincided with AMGEN trading at 96% of its 52-week high, following a 9.9% 30-day price return. Such a move suggests the AI system, operating with sector-balance and concentration rules, responded to the stock’s elevated price level in relation to its valuation metrics.
weight 0.270% → 0.210% (-0.060 pp)·stock up 5.3% in the 30 days before
Jul 17·entry $366.29·now $364.17
-0.58%
since Jul 17
PQUS · Weight increase · 2d
weight 0.270% → 0.290% (+0.020 pp)·stock up 5.6% in the 30 days before
Jun 7·entry $345.73·now $364.17Drifting
+5.33%
since Jun 7
AIEQ · Exit · 1d
Amplify ETFs' AIEQ, leveraging IBM Watson NLP across thousands of US equities, executed a swift removal of AMGEN from its portfolio on July 1, 2026, consistent with its daily rebalancing and high-turnover mandate. The fund's methodology, which ingests news, filings, and social posts to generate daily rankings, likely detected a shift in sentiment or fundamental outlook for AMGEN that pushed it out of the 140-180 stock selection. While AMGEN showed a +9.2% 30-day return, the AI's continuous evaluation may have identified other opportunities as more compelling or signaled a turning point for AMGEN relative to its current price at 93% of its 52-week high. This decisive exit underscores the AI's dynamic assessment, prioritizing its current ranking against the broad market rather than long-term holds.
weight 0.240% → 0 (exited)·stock up 9.8% in the 30 days before
Jul 1·entry $361.33·now $364.17
+0.79%
since Jul 1
AIEQ · New entry · 1d
weight 0 → 0.220% (new)·stock down 0.4% in the 30 days before
May 30·entry $329.13·now $364.17Chased
+10.65%
since May 30
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.
Buffett-style framework
Fails the frameworkas of Jul 5
AI ETF AIEQ is exiting its position in Amgen, aligning with this value investing framework's 'Fail' verdict due to financial health and valuation concerns. However, QRFT is increasing its weight and PQUS is holding, indicating mixed signals from the AI ETFs that diverge from the framework's assessment.
- Circle of CompetenceAmgen's established portfolio of patented drugs and diverse therapeutic areas allow for reasonable long-term cash flow projections, despite the inherent risks of R&D and patent expiration in biotechnology.
- Economic MoatAmgen possesses a durable economic moat primarily through its extensive portfolio of patented drugs, high regulatory barriers to entry, and significant scale in R&D and manufacturing.
- ManagementThe provided financial data does not offer sufficient information to evaluate management's candor, capital allocation discipline, or personal investment in the company.
- Financial HealthWhile the current ROE is very high, the absence of a 10-year ROE history, operating margin trend, and sufficient detail on debt and owner earnings prevents a conclusive assessment of long-term financial health.
- Margin of SafetyWith a P/E of 25.41, P/B of 20.36, and EV/EBITDA of 28.32, Amgen's current price does not present a clear margin of safety against a conservative estimate of its intrinsic value.
The analysis finds Amgen possesses a strong economic moat due to its patented drug portfolio and high regulatory barriers, and its business model suggests reasonable predictability for long-term cash flow projections. However, the assessment identifies significant concerns regarding financial health, primarily due to insufficient data to confirm the 10-year ROE criterion and a lack of clarity on debt structure and owner earnings. Furthermore, the current valuation multiples suggest the stock is trading at a premium, leaving no discernible margin of safety for investors.
Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.